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ajor limitations of ventricular assist devices have been the high incidence of
thromboembolic events, the requirement for systemic anticoagulation, and
the mechanical stability and duration of the device.1 The successful use of
axial flow pumps for left ventricular (LV) assistance has been limited by
thromboembolic events2 and pump thrombosis.3 Therefore, imaging of the devices is cru-
cial.4 The HeartMate II axial flow pump (Thoratec, Pleasanton, Calif) has shown a low
incidence of thromboembolic events and proper long-term mechanical function. Pump
thrombosis has not been reported. We report a case of thrombus formation 4 months after
HeartMate II implantation.
Clinical Summary
A 40-year-old male patient with severe coronary artery disease and myocardial infarction was
transferred to our hospital. An echocardiogram revealed an LV ejection fraction less than 10%
and apical LV aneurysm carrying a large thrombus. Because there was cardiac decompensation
and no reasonable option for revascularization, the decision was made to perform HeartMate II
implantation. The postoperative course was uneventful, and the patient was discharged in good
condition on postoperative day 28. For anticoagulation, Coumadin (international normalized
ratio 2.5–3.0) and aspirin 100 mg/d were administered.
Two months after discharge, the patient was hospitalized again because of intermittent high
power consumption by the device (level range: 7–12 watt). Coumadin was withdrawn by a local
hospital because of an episode of gastrointestinal bleeding. The patient had increasing dyspnea
and felt unwell overall, which corresponded to the periods of increased power consumption by
the device.
Routine diagnostic measures included blood analysis, radiography, electrocardiography,
echocardiography, and a check-up of device data (eg, flow and speed rates). Hemolysis was
investigated by lactate dehydrogenase, D-dimers, and free hemoglobin measurements. Left
ventricular assist device (LVAD)-controller data confirmed the intermittent high power
consumption values for a period of a few seconds; a suction alarm was not detected. An echo-
cardiogram showed only a small LV enlargement with an LV end-diastolic diameter increase
from 55 to 58 mm, not responding to an increase in pump speed. A thrombus was not detected
by echocardiography, and both inflow and outflow cannulae showed sufficient flow. An elec-
trocardiogram revealed sinus rhythm at physiologic rates. It was assumed that a thrombus at
the LVAD impeller inflow site may cause higher resistance and, consequently, power increase
of the motor leading to hemolysis.
Treatment of the putative thrombus was performed by hirudin (intravenously) with a target
activated partial thromboplastin time of 50 to 60 seconds during 18 days. Because of normal
LVAD data and improved overall conditions (including reduction in LV end-diastolic diame-
ter), the patient was discharged with an anticoagulative regimen of Coumadin and aspirin. Three
months later, the same symptoms occurred again: high power values (.10 watts) for a few
seconds corresponding to chest pain and dyspnea, and high values of lactate dehydrogenase
and free hemoglobin.
Computed tomographic scanning was performed to evaluate possible regional thrombus
formation in the device outflow tract using a 64-row multislice scanner (GE LightSpeed VCT,
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cubital vein with a 4 mL/sec flow rate. The scanning protocol con-
sisted of an aortic bolus triggering with a start delay of 5 seconds.
Computed tomographic scanning demonstrated the inner side of
the axial pump and the inflow and outflow cannulae but could not
prove the existence of a thrombus. The density of blood and clot
seemed similar and could not be differentiated by computed tomog-
raphy. However, a few artefacts compromised the scan (Figure 1).
After 289 days with the device, the patient underwent transplantation
and a thrombus in the LVAD inflow cannula was found (Figure 2).
Discussion
Withdrawal of anticoagulation is associated with an increased risk
for thrombus formation in patients with LVADs. In case of any
Figure 1. Computed tomographic scan demonstrating the
HeartMate II (Thoratec, Pleasanton, Calif).204 The Journal of Thoracic and Cardiovascular Surgery c Janbleeding event, such as acute gastrointestinal bleeding, it is impor-
tant to contact the LVAD center to discuss changes in the anticoagu-
lative regimen.A large preoperative LV thrombus formation seems
to be a risk factor for delayed pump thrombosis. In this case, it is
likely that a secondary thrombus formed after cessation of the
thrombolytic therapy. Another possibility is that hirudin did not
effectively dissolve the primary thrombus.
In the HeartMate II LVAD, an increase of power consumption
with signs of hemolysis and LV dilation seem to be crucial param-
eters to detect a device thrombosis. Although our patient became
symptomatic, sufficient pump flow was maintained at all times.
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